

CLINICAL CANCER RESEARCH

TABLE OF CONTENTS

HIGHLIGHTS

5773 Selected Articles from This Issue

SPECIAL FEATURES

CCR Translations

5775 Response to Anti-PD-1 in Microsatellite-Stable Colorectal Cancer: A STAT Need
Maliha Nusrat

See related article, p. 5887

5778 Protein Glycosylation: "New-yet-Old" Target for Immunotherapy

Jaydeep Bhat and Dieter Kabelitz

See related article, p. 5990

Reviews

5781 Radiation-induced Adaptive Response: New Potential for Cancer Treatment

C. Norman Coleman, Iris Eke, Adeola Y. Makinde, Sunita Chopra, Sandra Demaria, Silvia C. Formenti, Shannon Martello, Michelle Bylicky, James B. Mitchell, and Molykutty J. Aryankalayil

5791 Statins as Anticancer Agents in the Era of Precision Medicine

AC Joseph Longo, Jenna E. van Leeuwen, Mohamad Elbaz, Emily Branchard, and Linda Z. Penn

5801 Facts and Hopes in Immunotherapy of Soft-Tissue Sarcomas

Javier Martín-Broto, David S. Moura, and Brian A. Van Tine

PERSPECTIVES

5809 The Paradoxical Effects of COVID-19 on Cancer Care: Current Context and Potential Lasting Impacts

AC Alex Broom, Katherine Kenny, Alexander Page, Nicole Cort, Eric S. Lipp, Aaron C. Tan, David M. Ashley, Kyle M. Walsh, and Mustafa Khasraw

RESEARCH BRIEFS: CLINICAL TRIAL BRIEF REPORT

5814 Race-Dependent Differences in Risk, Genomics, and Epstein-Barr Virus Exposure in Monoclonal Gammopathies: Results of SWOG S0120

Madhav V. Dhodapkar, Rachael Sexton, Antje Hoering, Frits Van Rhee, Bart Barlogie, and Robert Orłowski

CLINICAL TRIALS: TARGETED THERAPY

5820 Palbociclib and Trastuzumab in HER2-Positive Advanced Breast Cancer: Results from the Phase II SOLT1-1303 PATRICIA Trial

Eva Ciruelos, Patricia Villagrasa, Tomás Pascual, Mafalda Oliveira, Sonia Pernas, Laia Paré, Santiago Escrivá-de-Romaní, Luis Manso, Barbara Adamo, Eduardo Martínez, Javier Cortés, Silvia Vazquez, Antonia Perelló, Isabel Garau, Mireia Melé, Noelia Martínez, Alvaro Montaña, Begoña Bermejo, Serafin Morales, María J. Echarri, Estela Vega, Blanca González-Farré, Débora Martínez, Patricia Galván, Jordi Canes, Paolo Nuciforo, Xavier Gonzalez, and Aleix Prat

5830 Phase I Study of P-cadherin-targeted Radioimmunotherapy with ⁹⁰Y-FF-21101 Monoclonal Antibody in Solid Tumors**AC** Vivek Subbiah, William Erwin, Osama Mawlawi, Asa McCoy, David Wages, Catherine Wheeler, Carlos Gonzalez-Lepera, Holly Liu, Homer Macapinlac, Funda Meric-Bernstam, David S. Hong, Shubham Pant, Dao Le, Elmer Santos, Jose Gonzalez, Jason Roszik, Takeaki Suzuki, Ruth Ann Subach, Timothy Madden, Mary Johansen, Fumiko Nomura, Hirokazu Satoh, Tadashi Matsuura, Masamichi Kajita, Eri Nakamura, Yuichi Funase, Satoshi Matsushima, and Gregory Ravizzini

TABLE OF CONTENTS

- 5843** ***PIK3CA* Mutation in the ShortHER Randomized Adjuvant Trial for Patients with Early HER2⁺ Breast Cancer: Association with Prognosis and Integration with PAM50 Subtype**

A C Valentina Guarneri, Maria Vittoria Dieci, Giancarlo Bisagni, Alba A. Brandes, Antonio Frassoldati, Luigi Cavanna, Antonino Musolino, Francesco Giotta, Anita Rimanti, Ornella Garrone, Elena Bertone, Katia Cagossi, Oriana Nanni, Federico Piacentini, Enrico Orvieto, Gaia Griguolo, Matteo Curtarello, Loredana Urso, Laia Paré, Nuria Chic, Roberto D'Amico, Aleix Prat, and Pierfranco Conte

- 5852** **Entospletinib in Combination with Induction Chemotherapy in Previously Untreated Acute Myeloid Leukemia: Response and Predictive Significance of *HOXA9* and *MEIS1* Expression**

A C Alison R. Walker, John C. Byrd, James S. Blachly, Bhavana Bhatnagar, Alice S. Mims, Shelley Orwick, Tara L. Lin, Howland E. Crosswell, Danjie Zhang, Mark D. Minden, Veerendra Munugalavada, Lauren Long, Jinfeng Liu, Yang Pan, Thomas Oellerich, Hubert Serve, Arati V. Rao, and William G. Blum

- 5860** **Phase Ib Study of Chemoprevention with Green Tea Polyphenon E and Erlotinib in Patients with Advanced Premalignant Lesions (APL) of the Head and Neck**

Dong M. Shin, Sreenivas Nannapaneni, Mihir R. Patel, Qiuying Shi, Yuan Liu, Zhengjia Chen, Amy Y. Chen, Mark W. El-Deiry, Jonathan J. Beitler, Conor E. Steuer, Steven M. Roser, Adam M. Klein, Taofeek K. Owonikoko, Suresh S. Ramalingam, Fadlo R. Khuri, Zhuo G. Chen, and Nabil F. Saba

CLINICAL TRIALS: IMMUNOTHERAPY

- 5869** **Tebentafusp, A TCR/Anti-CD3 Bispecific Fusion Protein Targeting gp100, Potently Activated Antitumor Immune Responses in Patients with Metastatic Melanoma**

A C Mark R. Middleton, Cheryl McAlpine, Victoria K. Woodcock, Pippa Corrie, Jeffrey R. Infante, Neil M. Steven, Thomas R. Jeffrey Evans, Alan Anthony, Alexander N. Shoushtari, Omid Hamid, Avinash Gupta, Antonella Vardeu, Emma Leach, Revashnee Naidoo, Sarah Stanhope, Sion Lewis, Jacob Hurst, Ita O'Kelly, and Mario Sznol

- 5879** **Efficacy and Tolerability of High- versus Low-dose Lenalidomide Maintenance Therapy of Multiple Myeloma after Autologous Blood Stem Cell Transplantation**

A C Roland Fenk, Aristoteles Giagounidis, Hartmut Goldschmidt, Michael Heinsch, Mathias Rummel, Nicolaus Kroger, Amelie Boquoi, David Lopez, Celina Gerrlich, Julia Baier, Svenja Liesenjohann, Katarzyna Hauck, Ingrida Savickaite, Elias K. Mai, Carlo Aul, Judith Strapsatsas, Ariane Dienst, Mustafa Kondakci, Rainer Haas, and Guido Kobbe

- 5887** **Multicenter Phase I/II Trial of Napabucasin and Pembrolizumab in Patients with Metastatic Colorectal Cancer (EPOC1503/SCOOP Trial)**

A C Akihito Kawazoe, Yasutoshi Kuboki, Eiji Shinozaki, Hiroki Hara, Tomohiro Nishina, Yoshito Komatsu, Satoshi Yuki, Masashi Wakabayashi, Shogo Nomura, Akihiro Sato, Takeshi Kuwata, Masahito Kawazu, Hiroyuki Mano, Yosuke Togashi, Hiroyoshi Nishikawa, and Takayuki Yoshino

See related commentary, p. 5775

- 5895** **Immunomodulation in Pomalidomide, Dexamethasone, and Daratumumab-Treated Patients with Relapsed/Refractory Multiple Myeloma**

A C William E. Pierceall, Michael D. Amatangelo, Nizar J. Bahlis, David S. Siegel, Adeeb Rahman, Oliver Van Oekelen, Paola Neri, Mary Young, Weiyuan Chung, Natalya Serbina, Samir Parekh, Amit Agarwal, and Anjan Thakurta

PRECISION MEDICINE AND IMAGING

- 5903** **Multiplex Immunofluorescence in Formalin-Fixed Paraffin-Embedded Tumor Tissue to Identify Single-Cell-Level PI3K Pathway Activation**

Konrad H. Stopsack, Ying Huang, Svitlana Tyekucheva, Travis A. Gerke, Clyde Bango, Habiba Elfandy, Michaela Bowden, Kathryn L. Penney, Thomas M. Roberts, Giovanni Parmigiani, Philip W. Kantoff, Lorelei A. Mucci, and Massimo Loda

- 5914** **TSPO-targeted PET and Optical Probes for the Detection and Localization of Premalignant and Malignant Pancreatic Lesions**

Allison S. Cohen, Jun Li, Matthew R. Hight, Eliot McKinley, Allie Fu, Adria Payne, Yang Liu, Dawei Zhang, Qing Xie, Mingfeng Bai, Gregory D. Ayers, Mohammed Noor Tantawy, Jarrod A. Smith, Frank Revetta, M. Kay Washington, Chanjuan Shi, Nipun Merchant, and H. Charles Manning

- 5926** **Circulating Tumor DNA Predicts Outcome from First-, but not Second-line Treatment and Identifies Melanoma Patients Who May Benefit from Combination Immunotherapy**

A C Gabriela Marsavela, Jenny Lee, Leslie Calapre, Stephen Q. Wong, Michelle R. Pereira, Ashleigh C. McEvoy, Anna L. Reid, Cleo Robinson, Lydia Warburton, Afaf Abed, Muhammad A. Khattak, Tarek M. Meniawy, Sarah-Jane Dawson, Shahneen Sandhu, Matteo S. Carlino, Alexander M. Menzies, Richard A. Scolyer, Georgina V. Long, Benhur Amanuel, Michael Millward, Melanie R. Ziman, Helen Rizos, and Elin S. Gray

- 5934** **Multimodal CEA-Targeted Image-Guided Colorectal Cancer Surgery using ¹¹¹In-Labeled SGM-101**

Jan Marie de Gooyer, Fortuné M.K. Elekonawo, Desirée L. Bos, Rachel S. van der Post, André Pèlerin, Bérénice Framery, Françoise Cailler, Alexander L. Vahrmeijer, Johannes H.W. de Wilt, and Mark Rijpkema

TABLE OF CONTENTS


- 5943** **Comprehensive Genomic Profiling of Gastroenteropancreatic Neuroendocrine Neoplasms (GEP-NENs)**
Alberto Puccini, Kelsey Poorman, Mohamed E. Salem, Davide Soldato, Andreas Seeber, Richard M. Goldberg, Anthony F. Shields, Joanne Xiu, Francesca Battaglin, Martin D. Berger, Ryuma Tokunaga, Madiha Naseem, Afsaneh Barzi, Syma Iqbal, Wu Zhang, Shivani Soni, Jimmy J. Hwang, Philip A. Philip, Stefania Sciallero, W. Michael Korn, John L. Marshall, and Heinz-Josef Lenz
- 5952** **Gene Networks Constructed Through Simulated Treatment Learning can Predict Proteasome Inhibitor Benefit in Multiple Myeloma**
AC Joske Ubels, Pieter Sonneveld, Martin H. van Vliet, and Jeroen de Ridder
- TRANSLATIONAL CANCER MECHANISMS AND THERAPY**
- 5962** **Epithelial-to-Mesenchymal Transition is a Cause of Both Intrinsic and Acquired Resistance to KRAS G12C Inhibitor in KRAS G12C-Mutant Non-Small Cell Lung Cancer**
Yuta Adachi, Kentaro Ito, Yuko Hayashi, Ryo Kimura, Tuan Zea Tan, Rui Yamaguchi, and Hiromichi Ebi
- 5974** **Acquired FGFR and FGF Alterations Confer Resistance to Estrogen Receptor (ER) Targeted Therapy in ER⁺ Metastatic Breast Cancer**
Pingping Mao, Ofir Cohen, Kailey J. Kowalski, Justin G. Kusiak, Jorge E. Buendia-Buendia, Michael S. Cuoco, Pedro Exman, Seth A. Wander, Adrienne G. Waks, Utthara Nayar, Jon Chung, Samuel Freeman, Orit Rozenblatt-Rosen, Vincent A. Miller, Federica Piccioni, David E. Root, Aviv Regev, Eric P. Winer, Nancy U. Lin, and Nikhil Wagle
- 5990** **Inhibition of MAN2A1 Enhances the Immune Response to Anti-PD-L1 in Human Tumors**
Sailing Shi, Shengqing Gu, Tong Han, Wubing Zhang, Lei Huang, Ziyi Li, Deng Pan, Jingxin Fu, Jun Ge, Myles Brown, Peng Zhang, Peng Jiang, Kai W. Wucherpennig, and X. Shirley Liu
See related commentary, p. 5778
- 6003** **PD1 Blockade Enhances ICAM1-Directed CAR T Therapeutic Efficacy in Advanced Thyroid Cancer**
Katherine D. Gray, Jaclyn E. McCloskey, Yogindra Vedvyas, Olivia R. Kalloo, Steve El Eshaky, Yanping Yang, Enda Shevlin, Marjan Zaman, Timothy M. Ullmann, Heng Liang, Dessislava Stefanova, Paul J. Christos, Theresa Scognamiglio, Andrew B. Tassler, Rasa Zarnegar, Thomas J. Fahey III, Moonsoo M. Jin, and Irene M. Min
- 6017** **Concentration-dependent Early Antivasular and Antitumor Effects of Itraconazole in Non-Small Cell Lung Cancer**
David E. Gerber, William C. Putnam, Farjana J. Fattah, Kemp H. Kernstine, Rolf A. Brekken, Ivan Pedrosa, Rachael Skelton, Jessica M. Saltarski, Robert E. Lenkinski, Richard D. Leff, Chul Ahn, Chyndhri Padmanabhan, Vaidehi Chembukar, Sahba Kasiri, Raja Reddy Kallem, Indhumathy Subramanian, Qing Yuan, Quyen N. Do, Yin Xi, Scott I. Reznik, Lorraine Pelosof, Brandon Faubert, Ralph J. DeBerardinis, and James Kim
- 6028** **Potent Activity of an Anti-ICAM1 Antibody-Drug Conjugate against Multiple Myeloma**
Daniel W. Sherbenou, Yang Su, Christopher R. Behrens, Blake T. Aftab, Olivia Perez de Acha, Megan Murnane, Shelby C. Bearrows, Byron C. Hann, Jeffery L. Wolf, Thomas G. Martin, and Bin Liu
- 6039** **Targeting Extracellular Matrix Remodeling Restores BRAF Inhibitor Sensitivity in BRAFi-resistant Melanoma**
Charles Marusak, Varsha Thakur, Yuan Li, Juliano T. Freitas, Patrick M. Zmina, Vijay S. Thakur, Mayland Chang, Ming Gao, Jiufeng Tan, Min Xiao, Yiling Lu, Gordon B. Mills, Keith Flaherty, Dennie T. Frederick, Benchun Miao, Ryan J. Sullivan, Tabea Moll, Genevieve M. Boland, Meenhard Herlyn, Gao Zhang, and Barbara Bedogni
- 6051** **CXCR3 and Cognate Ligands are Associated with Immune Cell Alteration and Aggressiveness of Pancreatic Ductal Adenocarcinoma**
Andrew Cannon, Christopher M. Thompson, H. Carlo Maurer, Pranita Atri, Rakesh Bhatia, Sean West, Dario Ghersi, Kenneth P. Olive, Sushil Kumar, and Surinder K. Batra
- 6064** **Steroid Sulfatase Stimulates Intracrine Androgen Synthesis and is a Therapeutic Target for Advanced Prostate Cancer**
Cameron M. Armstrong, Chengfei Liu, Liangren Liu, Joy C. Yang, Wei Lou, Ruining Zhao, Shu Ning, Alan P. Lombard, Jinge Zhao, Leandro S. D'Abronzio, Christopher P. Evans, Pui-Kai Li, and Allen C. Gao

AC icon indicates AuthorChoice
For more information please visit www.aacrjournals.org

TABLE OF CONTENTS

ABOUT THE COVER

Multiplex immunofluorescence for PI3K pathway activation on a single cell-level, using formalin-fixed paraffin-embedded (FFPE) prostate cancer tissue on tissue microarrays (TMA). The merged image shows the following markers: PTEN (orange), stathmin (aqua), phosphoS6 (green), p63 (red), AMACR (yellow), and DAPI counterstain (blue) in a TMA core with both normal tissue (center) and invasive tumor tissue. For details, see the article by Stopsack and colleagues on page 5903 of this issue.



Clinical Cancer Research

26 (22)

Clin Cancer Res 2020;26:5773-6074.

Updated version Access the most recent version of this article at:
<http://clincancerres.aacrjournals.org/content/26/22>

E-mail alerts [Sign up to receive free email-alerts](#) related to this article or journal.

Reprints and Subscriptions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, use this link <http://clincancerres.aacrjournals.org/content/26/22>.
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.